Epidemiology of CAP in Europe

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 1-12

  Singanayagam, Anika ^a   Chalmers, James D ^b   Welte, Tobias ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MACROLIDE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; AGE; ALCOHOL CONSUMPTION; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; EUROPE; FINLAND; GERMANY; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; ICD-10; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PNEUMOCOCCAL INFECTION; QUALITY OF LIFE; RISK FACTOR; SEPTIC SHOCK; SMOKING; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 84905756870     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10003013     Document Type: Article

References (82)

1. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68: 1057-1065.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
3. The burden of lung disease. In: Gibson GJ, Loddenkemper R, Sibille Y, et al. The European Lung White Book. Respiratory Health and Disease in Europe. Sheffield, European Respiratory Society, 2013; pp. 2-15.
4. Acute lower respiratory infections. In: Gibson GJ, Loddenkemper R, Sibille Y, et al., eds. The European Lung White Book. Respiratory Health and Disease in Europe. Sheffield, European Respiratory Society, 2013; pp. 210-223.
5. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
6. Guevara RE, Butler JC, Marston BJ, et al. Accuracy of ICD-9 CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol 1999; 149: 282-289.
7. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J2000; 15: 757-763.
8. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-988.
9. Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14: 727-733.
10. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
11. Kornum JB, Nørgaard M, Dethlefsen C, et al. Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J2010; 36: 1330-1336.
12. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106: 1124-1133.
13. Singanayagam A, Singanayagam A, Chalmers JD. Obesity is associated with improved survival in communityacquired pneumonia. Eur Respir J2013; 42: 180-187.
14. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54: 470-478.
15. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J2009; 1: 153-159.
16. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009; 103: 309-316.
17. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc)2011; 137: 533-540.
18. Bénard A, Mercié P, Alioum A, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS One 2010; 5: e8896.
19. Snijders B, van der Hoek W, Stirbu I, et al. General practitioners' contribution to the management of communityacquired pneumonia in the Netherlands: a retrospective analysis of primary care, hospital, and national mortality databases with individual data linkage. Prim Care Respir J2013; 22: 400-405.
20. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J2011; 38: 643-648.
21. Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity indexvsclinical judgement. Chest 2003; 124: 121-124.
22. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J2011; 37: 858-564.
23. Thomsen RW, Riis A, Norgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med 2006; 259: 410-417.
24. Froes F, Diniz A, Mesquita M, et al. Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009. Eur Respir J2013; 41: 1141-1146.
25. Christensen K, Doblhammer G, Rau R, et al. Aging populations: the challenges ahead. Lancet 2009; 374: 1196-1208.
26. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J2008; 31: 1274-1284.
27. Durando P, Faust SN, Fletcher M, et al. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect, 2013: Suppl. 1, 1-9.
28. Taylor JK, Fleming GB, Singanayagam A, et al. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. Am J Med 2013; 126: 995-1001.
29. Cabre M, Serra-Prat M, Palomera E, et al. Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia. Age Ageing 2010; 39: 39-45.
30. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
31. Calverley PMA. Inhaled corticosteroids as a cause of CAP. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 234-242.
32. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systemic review and meta-analysis. CMAJ2011; 183: 310-309.
33. Fillon KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for communityacquired pneumonia: replicated cohort studies with meta-analysis. Gut2013 [In press DOI: 10. 1136/gutjnl-2013-304738].
34. Blasi F, Mantero M, Santus P, et al. Understanding the burden of pneumococcal disease in adults. Clinical Microbiology and Infection 2012; 18: 7-14.
35. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in communityacquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37: 1409-1420.
36. Wunsch H, Angus DC, Harrison DA, et al. Comparison of medical admissions to intensive care units in the United States and United Kingdom. Am J Respir Crit Care Med 2011; 183: 1666-1673.
37. Bauer TT, Welte T, Strauss R, et al. Why do nonsurvivors from community-acquired pneumonia not receive ventilator support?Lung 2013; 191: 417-424.
38. Froes F. Pneumonia da comunidade no adulto em Portugal Continental-incidencia emortalidade dos internamentos hospitalares nos anos de 1998 a 2000 [Pneumonia in the adult population in continental Portugal-incidence and mortality in hospitalized patients from 1998 to 2000]. Rev Port Pneumol 2003; 9: 187-194.
39. Sintes H, Sibila O, Waterer GW, et al. Severity assessment tools in CAP. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 88-104.
40. Lung M, Rello J. Microbiology of bacterial CAP using traditional and molecular techniques. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 25-41.
41. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 159: 1550-1555.
42. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalisation following discharge of patients hospitalised with community-acquired pneumonia. Chest 2009; 136: 1079-1085.
43. Johnstone J, Eurich D, Majumdar S, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine 2008; 87: 329-334.
44. Yende S, Angus D, Ali IS, et al. Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007; 55: 518-525.
45. Singanayagam A, Elder DH, Chalmers JD. Is community-acquired pneumonia an independent risk factor for cardiovascular disease?Eur Respir J2012; 39: 187-196.
46. el Moussaoui R, Opmeer BC, de Borgie CAJM, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest 2006; 130: 1165-1172.
47. Monge V, San-Martin VM, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health 2001; 11: 362-364.
48. Dal Negro R, Berto P, Tognella S, et al. Cost-of-illness of lung disease in the Tri Veneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 2002; 57: 3-9.
49. Bartolomé M, Almirall J, Morera J, et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J2004; 23: 610-616.
50. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-2246.
51. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24: Suppl. 1, S85-S88.
52. Aspa J, Rajas O, Rodríguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38: 787-798.
53. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. NEJM1995; 333: 474-480.
54. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic resistant strains in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004; 38: 1570-1578.
55. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillinsusceptible pneumococcal disease. Paediatr Infect Dis J1995; 14: 885-890.
56. Mascimento-Carvalho C, Cardoso MR, Brandileone MC, et al. Penicillin/ampicillin efficacy among children with severe pneumonia due to penicillin-resistant pneumococcus (MIC54mgmL-1). J Med Microbiol 2009; 58: 1390-1392.
57. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4. 0, 2014. www. eucast. org/
58. Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteraemic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43: 432-438.
59. Fuller JD, Low DE. A review ofStreptococcus pneumoniaeinfection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41: 118-121.
60. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, ECDC, 2013; pp. 51-58.
61. Clinical and Laboratory. Standards Institute. M100-S24 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement. Wayne, Clinical Laboratory Standards Institute, 2014.
62. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistantStreptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-564.
63. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance inStreptococcus pneumoniaeand Streptococcus pyogenes. Emerg Infect Dis 2004; 10: 514-517.
64. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-282.
65. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of b-lactam: risk factors for carriage of penicillin-resistantStreptococcus pneumoniae. JAMA 1998; 279: 365-370.
66. Gonzales R, Malone DC, Maselli JH, et al. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33: 757-762.
67. Soares S, Kristinsson KG, Musser JM, et al. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniaefrom Spain to Iceland in the late 1980s. J Infect Dis 1993; 168: 158-163.
68. Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-306.
69. Liñares J, Ardanuy C, Pallares R, et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniaeover a 30-year period. Clin Microbiol Infect 2010; 16: 402-410.
70. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422.
71. Immunisation against respiratory diseases. In: Gibson GJ, Loddenkemper R, Sibille Y, et al, eds. The European Lung White Book. Respiratory Health and Disease in Europe. Sheffield, European Respiratory Society, 2013. pp. 306-315.
72. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptibleStreptococcus pneumoniain Alaska. J Infect Dis 2004; 190: 2031-2038.
73. Pletz MW, Welte T. Pneumococcal and influenza vaccination. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 266-284.
74. Ewig S, Welte T, Chastre J, et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10: 279-287.
75. Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia distinct entity needing specific therapy?Curr Opin Infect Dis 2012; 25: 166-175.
76. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy and clinical outcomes in healthcare associated pneumonia: a UK cohort study. Clin Infect Dis 2011; 53: 107-113.
77. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
78. Chalmers JD, Rother C, Salih W, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58: 330-339.
79. Ewig S. The pneumonia triad. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 13-24.
80. Aliberti S, Cillonez C, Chalmers JD, et al. Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68: 997-999.
81. Carratalà J, Mykietiuk A, Fernández-Sabé N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007; 167: 1393-1399.
82. Carrabba M, Zarantonello M, Bonara P, et al. Severity assessment of heathcare-associated pneumonia and pneumonia in immunosuppression. Eur Respir J2012; 40: 1201-1210.